The study aimed to investigate the potential anti-ageing effects of melatonin on the liver, kidney, and brain in rats with accelerated ageing induced by aluminum chloride (AlCl3) and D-galactose. Fifteen male albino Wistar rats were divided into three groups: a control group receiving normal saline, an accelerated ageing group receiving AlCl3 and D-galactose, and a melatonin-treated group receiving AlCl3, D-galactose, and melatonin. biochemical markers such as serum transaminases, oxidant /antioxidant enzymes, TNF-α, Bax and Bcl2 proteins, IL6 and SASP expression, and histopathological changes were assessed. Melatonin treatment mitigated hepatorenal and neural impairment in the aged rat group by reducing ALT, AST, urea, creatinine, TNF-α, and MDA levels. It also enhanced SOD activity and increased Bcl-2 levels while decreasing Bax and IL6/SASP expression. These findings suggest that melatonin may have therapeutic potential against oxidative stress and histopathological changes associated with ageing, likely due to its antioxidant, anti-apoptotic, and anti-inflammatory properties. Therefore, melatonin could be considered a protective agent against AlCl3 and D-galactose-induced ageing in rats.